Pilot Clinical Trial Results Following Historical Comparator Study Verify EnBrace HR is a Safe, Effective Alternative to Prescription Antidepressants for Women in Childbearing Years
|
LAFAYETTE, La., Feb. 26, 2019 /PRNewswire/ -- Women who struggle with depression during and around the time of pregnancy frequently opt to discontinue the use of antidepressants due to the possible risks to the fetus, putting themselves at jeopardy for depression relapse. Outcomes from the newly released Massachusetts General Hospital (MGH)/Harvard pilot clinical trial of JayMac Pharmaceuticals' EnBrace HR™ for the treatment of women seeking antidepressant alternatives for Major Depressive Disorder (MDD) in anticipation of or during pregnancy verify that EnBrace HR is an effective alternative. Women wanting to discontinue or minimize the use of antidepressants no longer need to choose between the safety of their baby and treatment of their depression. The efficacy observed in this study confirms that Rx EnBrace HR, an all-natural, nutritional prenatal vitamin with methylfolate, is an effective, safe option for treating and preventing depression in pregnancy and was well tolerated by patients. The findings from the clinical trial were published online this month in Annals of Clinical Psychiatry. In this study, EnBrace HR was investigated for depressive relapse prevention and for acute treatment of MDD in women planning pregnancy or during pregnancy. The study notes there is an evidence base for the antidepressant effects of the shared interconversion of folic acid, folinic acid and methylfolate, as found in EnBrace HR, showing significant improvement in perinatal depressive symptoms and providing a new treatment option for depression in pregnancy. Perinatal depression has been a critical public health concern and therapeutic dilemma for practitioners for years. MGH Center for Women's Mental Health states in its February 6, 2019 blog post that, "This pilot study suggests that EnBrace HR may be helpful for not only for preventing depressive relapse during pregnancy but may also have antidepressant effects…. While this was a small study, these results are exciting and we look forward to seeing more studies with EnBrace HR and similar compounds for women who are at risk for depression during pregnancy." JayMac Pharmaceuticals develops natural, evidence-based, root-cause treatments for psychiatric disorders that address genetic insufficiencies. Follow this link for the complete release (PDF). For additional information, visit http://www.enbracehr.com/ or call 985-788-7755. Media Contact:
SOURCE EnBrace HR |
View original content to download multimedia:
